"Aromatase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
| Descriptor ID |
D047072
|
| MeSH Number(s) |
D27.505.519.389.870.300 D27.505.696.399.450.327.149 D27.505.696.399.450.855.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aromatase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Aromatase Inhibitors".
This graph shows the total number of publications written about "Aromatase Inhibitors" by people in this website by year, and whether "Aromatase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2005 | 4 | 4 | 8 |
| 2006 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 2 | 5 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 4 | 6 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aromatase Inhibitors" by people in Profiles.
-
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025 Jun; 81:104448.
-
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. J Clin Oncol. 2024 Jun 20; 42(18):2149-2160.
-
Interventions to improve oral endocrine therapy adherence in breast cancer patients. J Cancer Surviv. 2025 Jun; 19(3):930-939.
-
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. Clin Cancer Res. 2023 04 14; 29(8):1468-1476.
-
Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clin Cancer Res. 2022 08 02; 28(15):3287-3295.
-
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med. 2021 12; 10(23):8581-8594.
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
-
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). J Natl Cancer Inst. 2020 07 01; 112(7):737-746.
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
-
Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects. Front Endocrinol (Lausanne). 2020; 11:277.